Audax is built around a team of extraordinary people distinguished by their creativity, expertise, determination and ambition.
Our superpower is deep immunology—made possible by our comprehensive in-house discovery and development capabilities. We evolve with the latest technologies but eschew trends in favour of testing carefully considered hypotheses.
We are building for the long-term, for the love of science and the people we hope to cure.
History
Founded in 2018, with a strong background in academic research, Audax (formerly oNKo-innate) has emerged as one of Australia’s leading independent biotechnology companies.
From an initial specialisation in fundamental lymphocyte biology, we have hit ‘fast-forward’ to prosecute some of the boldest targets in immuno-oncology and autoimmunity.
2018
Founded by Dr Jai Rautela and Professor Nicholas Huntington as oNKo-innate.
2019
Established our first research laboratories at Monash University, Australia.
2019
Developed a target discovery screening platform in immuno-oncology.
2020
Entered into a strategic research collaboration with Gilead Sciences, Inc. and Kite Pharma, Inc. focussed on the discovery of novel immuno-oncology targets and therapies.
2021
Awarded Australian Emerging Company of the Year at the AusBiotech and Jonhson & Johnson Industry Excellence Awards.
2022
Launched the Avikine® platform for the development of targeted cytokine therapies.
2023
Relocated and expanded our research laboratories within the Alfred Hospital precinct in Melbourne, Australia.
2024
Launched the Immunoglue™ molecular glue discovery platform.
2025
Initiated IND-enabling studies for our lead asset, DAX-044.
2025
Rebranded as Audax Biosciences, representing a bold vision to become an enduring Australian biotechnology company.
Partnerships
Audax has a history of building meaningful collaborations with like-minded organisations. Reach out to know more about partnering with us.